Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study to Test the Feasibility of the Combination of Gemcitabine and Anti-PD1 Monoclonal Antibody (CT-011) in the Treatment of Resected Pancreatic Cancer

NCT01313416 is registered in ClinicalTrials.gov with Augusta University as lead sponsor.

NCT NCT01313416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01313416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study to Test the Feasibility of the Combination of Gemcitabine and Anti-PD1 Monoclonal Antibody (CT-011) in the Treatment of Resected Pancreatic Cancer
Lead sponsor
Augusta University
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2012
Completion date
January 31, 2017
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of the pancreas, neoplasms pancreatic, pancreas cancer, pancreatic cancer, pancreatic neoplasms